Precision Medicine in Oncology® | Specialty

The Role of Venetoclax + Rituximab in CLL

January 28th 2020

Acalabrutinib, Second-Generation BTK Inhibitor for CLL

January 28th 2020

Long-Term Experience With BTK Inhibitors for CLL

January 28th 2020

Chemoimmunotherapy for CLL; Still a Role?

January 28th 2020

Mutation Status Throughout the CLL Clinical Course

January 28th 2020

Prognostic Factors in Patients With CLL

January 28th 2020

Precision Medicine Becomes More Widespread in Breast Cancer

January 27th 2020

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

Dr. Cheng on Molecular Testing Considerations in Prostate Cancer

January 25th 2020

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Dr. Tolaney on the Advantages of ctDNA Versus Tissue Biopsy in Breast Cancer

January 25th 2020

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLC

January 24th 2020

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

January 24th 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Dr. Gibbs on Testing for p16 and p21 in Osteosarcoma

January 23rd 2020

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers

January 22nd 2020

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Dr. Norden on Cost and Effectiveness of Genomic Testing

January 22nd 2020

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.

Dr. Sparano on the Utility of Liquid Biopsies in Breast Cancer

January 21st 2020

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.

Dr. Kasi on Utility of Personalized Medicine in Colorectal Cancer

January 21st 2020

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).

Incorporating Precision Medicine into Oncology

January 21st 2020

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

NICE Cites Uncertainty in Deciding Against Larotrectinib in NTRK Fusion+ Solid Tumors

January 18th 2020

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Utility of Trapelo to Increase Molecular Testing Rates

January 18th 2020

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Dr. Hudson on Repeat Molecular Testing in Relapsed/Refractory NSCLC

January 18th 2020

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.